2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6012 Immune reprogramming with axatilimab: CSF‑1R–dependent myeloid modulation and reduced CD4⁺ T‑cell activation in chronic graft‑versus‑host disease

Michael A Pratta, MS, Ian M. Catlett, PhD2, Isac Lee, PhD3, Angelina Volkova, PhD4, Kenzo Kinami, MBA5, Shintaro Ono, MD, PhD6, Jay Getsy, DMD, DO7, Naresh Punwani, PhD, MBA8, Li Li, MD, PhD9, Muharrem Muftuoglu, MD10
1 Incyte Corporation, Wilmington, Delaware, United States
2 Incyte Corporation, Wilmington, Delaware, United States
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Incyte Biosciences Japan GK, Tokya, Japan
6 Incyte Biosciences Japan GK, Tokya, Japan
7 Incyte Corporation, Wilmington, Delaware, United States
8 Incyte Corporation, Wilmington, Delaware, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: Axatilimab (AXA), a monoclonal antibody targeting the colony-stimulating factor 1 receptor (CSF‑1R), modulates myeloid cell homeostasis in patients with chronic graft-versus-host disease (cGVHD). AXA exposure has been associated with increased circulating levels of CSF‑1R ligands (colony-stimulating factor 1 [CSF‑1] and interleukin-34 [IL‑34]) and reduced CSF‑1R–expressing nonclassical monocytes (NCMs).

Aims: We used mass cytometry to characterize the effect of AXA on immune cell populations in healthy volunteers and patients with cGVHD.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and cryopreserved for subsequent analysis. PBMCs were collected at multiple time points before and after AXA infusion from healthy volunteers enrolled in a phase 1 study in Japan (jRCT2071220109) who received AXA intravenously (IV) at 0.3 mg/kg (n=6) or 1 mg/kg (n=9), or placebo (n=5). Data from Japanese healthy volunteers were compared with those from healthy volunteers in the US (NCT06713590) who received a single IV dose of AXA 0.3 mg/kg (n=9), and from Japanese patients with cGVHD (NCT06263478) who were treated with AXA IV 0.3 mg/kg every 2 weeks (Q2W; n=18), with each treatment cycle defined as 28 days. PBMCs from each study were analyzed for high-dimensional immune profiling by mass cytometry at Teiko.bio (Salt Lake City, UT, USA) using a qualified panel adapted from a panel originally described in Holtan SG et al. Transplant Cell Ther. 2023;29(8):509.e1-509.e8. The panel enabled detection of B cells, T cells, dendritic cells, natural killer (NK) cells, and monocytes, and included cell-surface markers such as CSF‑1R, cluster of differentiation (CD)25, CD38, CD11b, and CD11c.

Results: Among healthy volunteers in the US receiving a single IV dose of AXA 0.3 mg/kg, mass cytometry demonstrated a transient increase in NCMs at 4 hours post‑infusion, followed by a reduction at 72 hours and a return to baseline by 168 hours (Day 7). Aggregate uniform manifold approximation and projection (UMAP) analysis across all time points and donors revealed an apparent discontinuity in the classical-to-nonclassical (classical monocyte [CM]→intermediate monocyte [IM]→NCM) monocyte transition at 24 hours, followed by near-complete loss of the IM and NCM populations at 72 hours. Similar kinetics in NCMs were observed in healthy Japanese volunteers receiving comparable AXA IV dosing using a similar mass cytometry panel and gating strategy. Among Japanese patients with cGVHD treated with AXA IV 0.3 mg/kg Q2W, NCMs were reduced at Cycle (C)1 Day (D)8 and returned to baseline by C2D1 and C4D1, consistent with the temporal pattern observed in healthy volunteers with more frequent sampling. Mass cytometry further revealed a redistribution within the NCM compartment, characterized by an apparent transient expansion of CD38⁺CD11b⁺ cells and a concomitant reduction in CD11c⁺ cells. The expanded CD38⁺CD11b⁺ subset likely reflects mobilization of tissue-resident, CSF‑1R–dependent monocytes into the circulation and represents a metabolically active, adhesion-competent phenotype potentially sustained by alternative signaling pathways. In contrast, depletion of CD11c⁺ NCMs, an antigen-presenting, tissue-trafficking subset, suggests selective impairment of inflammatory, CSF‑1R–dependent monocyte populations despite comparable CSF‑1R expression levels, highlighting functional heterogeneity within the NCM compartment. Beyond monocytes, AXA was associated with broader immune remodeling, including expansion of CD38⁺ dendritic cells and a downward trend in activated CD25⁺CD4⁺ T cells, while total CD4⁺ T cell numbers remained stable.

Conclusion: These findings support an indirect mechanism whereby CSF‑1R blockade attenuates antigen-driven CD4⁺ T cell activation through modulation of myeloid and dendritic cell function rather than direct lymphodepletion. Collectively, the coordinated immunologic shifts indicate that AXA reprograms CSF‑1R–dependent myeloid lineages toward a less inflammatory state, providing a mechanistic basis for its clinical activity in cGVHD and suggesting a broader role for macrophage-targeted therapies in immune reconstitution. These observations warrant confirmation in future clinical studies.
Michael A Pratta, MS: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment